4f521ce8-4aac-4ea5-abbe-732ff9ac5409
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- HEDGEHOG_SIGNALING+0.300
- KRAS_SIGNALING_DN+0.300
- MYOGENESIS+0.300
- APICAL_JUNCTION+0.200
- APICAL_SURFACE+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- GLYCOLYSIS+0.200
- P53_PATHWAY+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- ANDROGEN_RESPONSE-0.400
- ANGIOGENESIS-0.400
- PROTEIN_SECRETION-0.400
- UV_RESPONSE_DN-0.400
- G2M_CHECKPOINT-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c2e34dda-0852-492e-9cde-3ff606259c12 | — | — | 0.871 |
| 2 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.869 |
| 3 | 3e1c728a-cf38-4ca8-9d87-0bbf098567a6 | — | — | 0.866 |
| 4 | ea9f5a96-93d4-4724-bc4b-2813fa8a35ae | — | — | 0.863 |
| 5 | 0ffd0bed-35a4-4fec-9d56-1d4ae5dcb507 | — | — | 0.835 |
| 6 | 13e18e29-9f8a-4bd4-9a5d-e6c30668d07a | — | — | 0.834 |
| 7 | SRR25043618 | — | — | 0.821 |
| 8 | MNG559 | — | — | 0.811 |
| 9 | f17e12f0-54ed-4dc2-ab7e-22a1f90e1405 | — | — | 0.802 |
| 10 | 84f39507-9883-4bab-98f9-8bd72d2aee7b | — | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |